InnoCentive recently partnered with the ALS Association and Teva Pharmaceutical Industries Ltd. (“Teva”) to create and release a premium challenge aimed at helping find treatments for people with neurodegenerative diseases like Amyotrophic lateral sclerosis (ALS). InnoCentive has previously awarded Solvers over $1M for solutions in the field of ALS research.
The challenge is now closed to new submissions and two winning Solvers were found and named. There were 217 InnoCentive Solvers from 42 countries that initially engaged, which resulted in 38 solutions/proposals submitted by solvers located in 16 different countries. This demonstrates the reach, strength and diversity of solvers attracted to open innovation challenges that leverage InnoCentive’s growing expert community of prepared minds.
The purpose of the challenge was to find treatment options for the disorders are limited and new approaches to improve patient outcomes are needed. Teva was seeking proposals for novel intracellular or extracellular targets with therapeutic potential to alleviate the conditions of people suffering from neurodegenerative diseases, migraine and headache disorders, and pain.
Two Awards Were Given
InnoCentive is pleased to announce that the ALS Association and Teva granted two awards to solvers from our network as a result of the crowdsourcing innovation challenge. The winning solvers were:
- Philip C. Wong, Ph.D., of Johns Hopkins University School of Medicine, for TDP-43 dependent splicing repression as a mechanism-based therapeutic target for ALS.
- Jonathan C. Grima, Ph.D., and Jeffrey D. Rothstein, M.D., Ph.D., of Johns Hopkins University School of Medicine, for targeting the nuclear pore in neurodegeneration.
Working Towards a Cure
As of today, there is no known cure for ALS, and treatment options are limited. Only two drugs are approved by the FDA for use in the U.S. The work these solvers have accomplished to help bring new treatments to the more than 20,000 people suffering from the condition is invaluable.
Looking Towards the Future
New treatments are desperately needed for ALS, and we look forward to working with the ALS Association and Teva in the future to help them leverage our global solver network to bring new innovations that help ALS patients. This is just another testament to the power of open innovation. We want to thank all the solvers who participated in the challenge.
If you are interested in joining our solver network, get in touch with us today.